Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LianBio’s Partner BMS OK’d to Launch Cardiomyopathy Drug in US

publication date: Apr 29, 2022

LianBio, a Shanghai-Princeton in-licensing company, reported its partner, Bristol-Myers Squibb, was approved for a US launch of Camzyos™ (mavacamten) as a therapy for obstructive hypertrophic cardiomyopathy (obstructive HCM). In 2020, LianBio in-licensed China/SE Asia rights to the drug from MyoKardia in a deal worth $188 million. MyoKardia was subsequently acquired by BMS. LianBio is conducting a China Phase III double-blind, randomized, placebo-controlled registrational study of mavacamten to determine its safety and efficacy in China patients with HCM. More details....

Stock Symbols: (NSDQ: LIAN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital